Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
复制标题
DOI：
10.1016/j.lfs.2020.117477
复制
发表时间：
2020-05-01
期刊：
影响因子：
6.1
通讯作者：
Elfiky, Abdo A.
中科院分区：
文献类型：
--
作者：
Elfiky, Abdo A.
目的：两个月前在中国武汉报告了一种新出现的人类冠状病毒（HCoV）（COVID-19）。到目前为止，8万例确诊病例中有2700多人死亡，主要发生在中国和其他40个国家。一个月前，中国证实了COVID-19的人际传播。根据世界卫生组织（WHO）的报告，SARS HCoV造成了超过8000例病例，其中774例死亡。此外，MERS HCoV导致约2500例报告病例中的858例死亡。本研究旨在检测抗HCV药物对COVID-19 RNA依赖性RNA聚合酶（RdRp）的作用。材料与方法：本研究采用序列分析、建模和对接等方法构建武汉COVID-19 RdRp模型。此外，新出现的武汉HCoV RdRp模型被抗聚合酶药物靶向，包括已批准的药物Sofosbuvir和Ribavirin。关键发现：结果表明Sofosbuvir，IDX-184，Ribavirin和Removivir作为对抗新出现的HCoV疾病的有效药物的有效性。意义：本研究为COVID-19 RdRp提供了一个完美的模型，使其能够在计算机上测试抗聚合酶药物。此外，这项研究还提出了一些药物，以前证明了它对新出现的病毒感染的有效性。
Aims: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today > 2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for > 8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp).Materials and methods: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin.Key findings: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease.Significance: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.